RxDoctor Payments Data

Alexis Vanbastelaer

Acute Care · Gainesville, GANPI 1679273882

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.4% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 30.8% of the total. Among acute care clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,548in general payments, 2019–2025

Across 132 payments — averaging $26.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Ardelyx, Inc.$434
  • Sanofi$422
  • Johnson & Johnson$375
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$268
  • Boston Scientific$181
  • plus $774 from 15 others

What the payments were for

  • Food & beverage$3,35094%
  • Education$1986%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,548 in reported general payments places this provider in the 90th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Medicare billing

Part B allowed, 2024
$41,402
Medicare patients
400
Services billed
494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf117$18,756
LinzessLinaclotide28$16,412
MovantikNaloxegol Oxalate21$8,570
Pantoprazole Sodium384$2,894
Lubiprostone19$2,846
CholestyramineCholestyramine (With Sugar)37$2,600
Famotidine175$1,477
Colestipol Hcl36$1,147
Omeprazole94$840
Mesalamine12$797
Sucralfate23$627
Ondansetron OdtOndansetron171$453
Lansoprazole23$233
Esomeprazole Magnesium11$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,094$16,41228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 679 acute care providers in Georgia.

Other acute care in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →